胡元一;张启栋;

• 1:北京中医药大学第三附属医院微创关节科
• 2:中日友好医院骨科一部

摘要(Abstract)：

骨关节炎是一种关节退行性疾病,其特征是关节软骨和软骨下骨逐渐丧失,并伴有不同程度的滑膜炎症。糖皮质激素具有强大的抗炎作用,能对抗各种原因如物理、化学、生物、免疫等引起的炎症。因其抗炎止痛效果好、作用迅速,临床常常应用合成糖皮质激素治疗骨关节炎,尤其是在关节腔注射治疗中。本综述将探讨糖皮质激素在骨关节炎中的研究进展,以期为优化骨关节炎疗法提供参考。

关键词(KeyWords)： 骨关节炎;粮皮质激素;机制

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金（编号：81703896）

作者(Author): 胡元一;张启栋;

Email:

DOI:

参考文献(References)：

• [1] van Meurs J B. Osteoarthritis year in review 2016:genetics, genomics and epigenetics[J]. Osteoarthritis Cartilage, 2017, 25(2):181-189.
• [2] Barnett R. Osteoarthritis[J]. Lancet, 2018, 391(10134):1985.
• [3] Malemud CJ. Biologic basis of osteoarthritis:state of the evidence[J]. Curr Opin Rheumatol, 2015, 27(3):289-294.
• [4] Courties A, Sellam J. Osteoarthritis and type 2 diabetes mellitus:what are the links[J]. Diabetes Res Clin Pract, 2016, 122:198-206.
• [5] Orlowsky EW, Kraus VB. The role of innate immunity in osteoarthritis:when our first line of defense goes on the offensive[J]. J Rheumatol, 2015, 42(3):363-371.
• [6] Abou-Raya A, Abou-Raya S, Khadrawi T, et al. Effect of lowdose oral prednisolone on symptoms and systemic inflammation in older adults with moderate to severe knee osteoarthritis:a randomized placebo-controlled trial[J]. J Rheumatol, 2014, 41(1):53-59.
• [7] Matzkin EG, Curry EJ, Kong Q, et al. Efficacy and treatment response of intra-articular corticosteroid injections in patients with symptomatic knee osteoarthritis[J]. J Am Acad Orthop Surg,2017, 25(10):703-714.
• [8] Grodzinsky AJ, Wang Y, Kakar S, et al. Intra-articular dexamethasone to inhibit the development of post-traumatic osteoarthritis[J]. J Orthop Res, 2017, 35(3):406-411.
• [9]覃海容,祝最成.玻璃酸钠联合地塞米松治疗膝关节骨性关节炎的效果及对膝关节功能的影响[J].临床医学工程, 2017, 24(1):69-70.
• [10]孙大伟.地塞米松联合玻璃酸钠治疗膝骨性关节炎的疗效研究[J/CD].中西医结合心血管病电子杂志, 2019, 7(30):51.
• [11]姚永.透明质酸联合糖皮质激素关节腔注射治疗膝关节炎疗效分析[J].中国医药科学, 2011, 1(22):82, 84.
• [12]中华医学会骨科学分会关节外科学组.骨关节炎诊疗指南(2018年版)[J].中华骨科杂志, 2018, 38(12):705-715.
• [13] Johnston PC, Lansang MC, Chatterjee S, et al. Intra-articular glucocorticoid injections and their effect on hypothalamic-pituitaryadrenal(HPA)-axis function[J]. Endocrine, 2015, 48(2):410-416.
• [14] Hartmann K, Koenen M, Schauer S, et al. Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy[J]. Physiol Rev, 2016, 96(2):409-447.
• [15] Mihailidou C, Panagiotou C, Kiaris H, et al. Crosstalk between C/EBP homologous protein(CHOP)and glucocorticoid receptor in lung cancer[J]. Mol Cell Endocrinol, 2016, 436:211-223.
• [16] Zimmermann GR, Avery W, Finelli AL, et al. Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug[J]. Arthritis Res Ther, 2009, 11(1):R12.
• [17] Malaise O, Relic B, Charlier E, et al. Glucocorticoid-induced leucine zipper(GILZ)is involved in glucocorticoid-induced and mineralocorticoid-induced leptin production by osteoarthritis synovial fibroblasts[J]. Arthritis Res Ther, 2016, 18(1):219.
• [18] Ng HP, Jennings S, Wang J, et al. Non-canonical glucocorticoid receptor transactivation of gilz by alcohol suppresses cell inflammatory response[J]. Front Immunol, 2017, 8:661.
• [19] Scotece M, Mobasheri A. Leptin in osteoarthritis:focus on articular cartilage and chondrocytes[J]. Life Sci, 2015, 140(1):75-78.
• [20] Lu YC, Evans CH, Grodzinsky AJ. Effects of short-term glucocorticoid treatment on changes in cartilage matrix degradation and chondrocyte gene expression induced by mechanical injury and inflammatory cytokines[J]. Arthritis Res Ther, 2011, 13(5):R142.
• [21] Li Y, Wang Y, Chubinskaya S, et al. Effects of insulin-like growth factor-1 and dexamethasone on cytokine-challenged cartilage:relevance to post-traumatic osteoarthritis[J]. Osteoarthritis Cartilage, 2015, 23(2):266-274.
• [22] Kato Y, Gospodarowicz D. Stimulation by glucocorticoid of the synthesis of cartilage-matrix proteoglycans produced by rabbit costal chondrocytes in vitro[J]. J Biol Chem, 1985, 260(4):2364-2373.
• [23] Wernecke C, Braun HJ, Dragoo JL. The effect of intra-articular corticosteroids on articular cartilage:a systematic review[J]. Orthop J Sports Med, 2015, 3(5):1806628587.
• [24] Conde J, Lazzaro V, Scotece M, et al. Corticoids synergize with IL-1 in the induction of LCN2[J]. Osteoarthritis Cartilage, 2017, 25(7):1172-1178.
• [25] Quiros-Gonzalez I, Yadav VK. Central genes, pathways and modules that regulate bone mass[J]. Arch Biochem Biophys, 2014,561(1):130-136.
• [26] Kleine SA, Budsberg SC. Synovial membrane receptors as therapeutic targets:a review of receptor localization, structure, and function[J]. J Orthop Res, 2017, 35(8):1589-1605.
• [27] Malaise O, Relic B, Quesada-Calvo F, et al. Selective glucocorticoid receptor modulator compound A, in contrast to prednisolone,does not induce leptin or the leptin receptor in human osteoarthritis synovial fibroblasts[J]. Rheumatology(Oxford), 2015, 54(6):1087-1092.
• [28] Wei B, Zhu Z, Xiang M, et al. Corticosterone suppresses IL-1 beta-induced mPGE2 expression through regulation of the 11betaHSD1 bioactivity of synovial fibroblasts in vitro[J]. Exp Ther Med, 2017, 13(5):2161-2168.